Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Keita Fukuyama

Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next‐Generation Sequencing‐Based Multiplex Gene Panel Assay

Oncologist

English

MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients With Stage II/III Colorectal Cancer

English

Related publications

The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-Cancer-Gene Panel

Journal of Cancer

Oncology

2018

English

Targeted Therapy According to Next Generation Sequencing-Based Panel Sequencing

Fukushima Journal of Medical Sciences

Medicine

2018

English

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer

Frontiers in Oncology

Cancer Research

Oncology

2020

English

Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis

Journal of Molecular Diagnostics

English

Size Matters: Dissecting Key Parameters for Panel-Based Tumor Mutational Burden (TMB) Analysis

International Journal of Cancer

Cancer Research

Oncology

2018

English

P2.09-15 a Next Generation Sequencing (NGS) RNA-Scan Multiplex Panel (QIAseq) to Identify Gene-Rearranged Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Rapid Whole-Genome Mutational Profiling Using Next-Generation Sequencing Technologies

Genome Research

Genetics

2008

English

Comprehensive Characterization of Mutations, Gene Expression, and Immune Repertoires in Malignant Lymphoma by Anchored Multiplex PCR and Next-Generation Sequencing

Hematological Oncology

English

Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Keita Fukuyama

Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next‐Generation Sequencing‐Based Multiplex Gene Panel Assay

MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients With Stage II/III Colorectal Cancer

Related publications

The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-Cancer-Gene Panel

Targeted Therapy According to Next Generation Sequencing-Based Panel Sequencing

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer

Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis

Size Matters: Dissecting Key Parameters for Panel-Based Tumor Mutational Burden (TMB) Analysis

P2.09-15 a Next Generation Sequencing (NGS) RNA-Scan Multiplex Panel (QIAseq) to Identify Gene-Rearranged Non-Small Cell Lung Cancer

Rapid Whole-Genome Mutational Profiling Using Next-Generation Sequencing Technologies

Comprehensive Characterization of Mutations, Gene Expression, and Immune Repertoires in Malignant Lymphoma by Anchored Multiplex PCR and Next-Generation Sequencing

Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden